

# Mondher Toumi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1408355/publications.pdf>

Version: 2024-02-01

127  
papers

2,796  
citations

186265

28  
h-index

223800

46  
g-index

133  
all docs

133  
docs citations

133  
times ranked

3724  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal symptomatic interactions in long-standing schizophrenia: a novel five-point analysis based on directed acyclic graphs. <i>Psychological Medicine</i> , 2023, 53, 1371-1378.	4.5	4
2	Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. <i>Health Policy</i> , 2022, 126, 49-59.	3.0	7
3	Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review. <i>Regenerative Medicine</i> , 2022, 17, 119-139.	1.7	5
4	Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment. <i>Frontiers in Public Health</i> , 2022, 10, 773629.	2.7	5
5	Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study. <i>Schizophrenia Research</i> , 2022, 244, 21-28.	2.0	2
6	Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. <i>Vaccine</i> , 2022, 40, 4008-4016.	3.8	12
7	Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts. <i>Vaccine</i> , 2022, 40, 3999-4007.	3.8	17
8	Systematic literature review on implicit factors influencing the HTA deliberative processes in Europe. <i>Journal of Market Access &amp; Health Policy</i> , 2022, 10, .	1.5	0
9	Point-of-care test screening versus Case finding for paediatric coeliac disease: A pragmatic study in primary care. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 337-339.	1.5	2
10	Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 29-44.	2.1	7
11	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. <i>Drug Discovery Today</i> , 2021, 26, 399-415.	6.4	20
12	Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. <i>Journal of Market Access &amp; Health Policy</i> , 2021, 9, 1887664.	1.5	2
13	Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 281-304.	2.1	11
14	Stigma in visible skin diseases – a literature review and development of a conceptual model. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1493-1504.	2.4	38
15	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	3.5	13
16	The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. <i>Drug Discovery Today</i> , 2021, 26, 2269-2281.	6.4	10
17	Factors influencing the COVID-19 daily deaths' peak across European countries. <i>Public Health</i> , 2021, 194, 135-142.	2.9	14
18	Partnership agreements for regenerative medicines: a database analysis and implications for future innovation. <i>Regenerative Medicine</i> , 2021, 16, 733-755.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 1145-1158.	1.4	4
20	Vaccine market access pathways in the EU27 and the United Kingdom – analysis and recommendations for improvements. Vaccine, 2021, 39, 5706-5718.	3.8	13
21	An Overview of Cell and Gene Therapy Development in China. Human Gene Therapy, 2021, , .	2.7	2
22	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health, 2021, 198, 230-237.	2.9	70
23	Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. Health Policy, 2021, 125, 1550-1556.	3.0	11
24	Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. Clinical Drug Investigation, 2021, 41, 929-939.	2.2	6
25	Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers. Frontiers in Public Health, 2021, 9, 754482.	2.7	2
26	An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models. Journal of Market Access & Health Policy, 2021, 9, 2002006.	1.5	6
27	Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes. Journal of Medical Economics, 2021, 24, 1280-1289.	2.1	6
28	On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe. Journal of Market Access & Health Policy, 2021, 9, 2002008.	1.5	9
29	Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries. Frontiers in Pharmacology, 2021, 12, 750742.	3.5	9
30	The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling. Psychological Medicine, 2020, 50, 566-574.	4.5	12
31	Health-related quality of life of patients after ischaemic stroke treated in a provincial hospital in Poland. Journal of Market Access & Health Policy, 2020, 8, 1775933.	1.5	7
32	Gene therapy randomised clinical trials in Europe – a review paper of methodology and design. Journal of Market Access & Health Policy, 2020, 8, 1847808.	1.5	2
33	Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials. Cardiovascular Therapeutics, 2020, 2020, 1-11.	2.5	9
34	Chinese guidelines related to novel coronavirus pneumonia. Journal of Market Access & Health Policy, 2020, 8, 1818446.	1.5	31
35	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. Journal of Market Access & Health Policy, 2020, 8, 1822666.	1.5	18
36	Current state of developing advanced therapies for rare diseases in the European Union. Expert Opinion on Orphan Drugs, 2020, 8, 417-429.	0.8	5

#	ARTICLE	IF	CITATIONS
37	A critical analysis and review of Lancet COVID-19 hydroxychloroquine study. <i>Journal of Market Access &amp; Health Policy</i> , 2020, 8, 1809236.	1.5	1
38	Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al. <i>Journal of Market Access &amp; Health Policy</i> , 2020, 8, 1758390.	1.5	9
39	Regenerative medicine regulatory policies: A systematic review and international comparison. <i>Health Policy</i> , 2020, 124, 701-713.	3.0	24
40	Managed Entry Agreements: Policy Analysis From the European Perspective. <i>Value in Health</i> , 2020, 23, 425-433.	0.3	64
41	Second opinions, multiple physician appointments, and overlapping prescriptions in the paediatric population: A systematic literature review. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1761-1767.	1.8	2
42	Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2019, 35, 1867-1872.	1.9	7
43	Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. <i>BMC Infectious Diseases</i> , 2019, 19, 655.	2.9	49
44	Measuring health-related quality of life in young children: how far have we come?. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1618661.	1.5	72
45	Economic burden for Alzheimer's disease in China from 2010 to 2050: a modelling study. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1667195.	1.5	15
46	Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1648973.	1.5	8
47	Why "American Patients First" is likely to raise drug prices outside of the United States. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1650596.	1.5	1
48	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , 2019, 35, 785-792.	1.9	13
49	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. <i>Value in Health</i> , 2019, 22, 661-668.	0.3	61
50	Non-profit drug research and development: the case study of Genethon. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1545514.	1.5	5
51	Characteristics of doctor-shoppers: a systematic literature review. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1595953.	1.5	43
52	President Trump's prescription to reduce drug prices: from the campaign trail to American Patients First. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1579597.	1.5	2
53	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Journal of Market Access &amp; Health Policy</i> , 2019, 7, 1574541.	1.5	31
54	PNS12 FACTORS TO BE CONSIDERED TO ENSURE ACCEPTABILITY OF HISTORICALLY CONTROLLED STUDIES BY HTA BODIES. <i>Value in Health</i> , 2019, 22, S764-S765.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 27-36.	1.4	18
56	Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment. Recent Results in Cancer Research, 2019, 213, 39-55.	1.8	2
57	Orphan Drugs in Oncology. Recent Results in Cancer Research, 2019, 213, 109-142.	1.8	5
58	Oncology from an HTA and Health Economic Perspective. Recent Results in Cancer Research, 2019, 213, 25-38.	1.8	3
59	Patient-Reported Outcomes in Oncology, Beyond Randomized Controlled Trials. Recent Results in Cancer Research, 2019, 213, 57-65.	1.8	7
60	The diversity in regenerative medicines regulations in Europe, USA and Japan. Cell & Gene Therapy Insights, 2019, 5, 1031-1042.	0.1	2
61	Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations. Cell & Gene Therapy Insights, 2019, 5, 1043-1059.	0.1	7
62	Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration. Journal of Market Access & Health Policy, 2018, 6, 1433426.	1.5	4
63	Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health, 2018, 21, 493-500.	0.3	75
64	Non-profit Drug Research and Development at a Crossroads. Pharmaceutical Research, 2018, 35, 52.	3.5	6
65	Funding breakthrough therapies: A systematic review and recommendation. Health Policy, 2018, 122, 217-229.	3.0	35
66	PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES.. Value in Health, 2018, 21, S363.	0.3	2
67	PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA. Value in Health, 2018, 21, S375-S376.	0.3	1
68	PRM146 - CURRENT AND FUTURE TRENDS IN METHODOLOGIES OF SURVIVAL CURVE EXTRAPOLATION IN ONCOLOGY ACCEPTED BY HTA AUTHORITIES.. Value in Health, 2018, 21, S381.	0.3	1
69	Patient-reported outcome claims in European and United States orphan drug approvals. Journal of Market Access & Health Policy, 2018, 6, 1542920.	1.5	7
70	Health related quality of life in patients having schizophrenia negative symptoms â€œ a systematic review. Journal of Market Access & Health Policy, 2018, 6, 1517573.	1.5	8
71	Primary cesarean delivery rate: Potential impact of a checklist. Journal of Gynecology Obstetrics and Human Reproduction, 2018, 47, 419-424.	1.3	8
72	Systematic review of pharmacoeconomic models for schizophrenia. Journal of Market Access & Health Policy, 2018, 6, 1508272.	1.5	6

#	ARTICLE	IF	CITATIONS
73	Gene therapies development: slow progress and promising prospect. Journal of Market Access & Health Policy, 2017, 5, 1265293.	1.5	91
74	Key drivers for market penetration of biosimilars in Europe. Journal of Market Access & Health Policy, 2017, 5, 1272308.	1.5	64
75	Filling the gap in CNS drug development: evaluation of the role of drug repurposing. Journal of Market Access & Health Policy, 2017, 5, 1299833.	1.5	28
76	Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe. Journal of Market Access & Health Policy, 2017, 5, 1299665.	1.5	31
77	A comparative study of orphan drug prices in Europe. Journal of Market Access & Health Policy, 2017, 5, 1297886.	1.5	23
78	Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. Journal of Market Access & Health Policy, 2017, 5, 1283105.	1.5	8
79	No correlation between the prices of oncology orphan drugs in the US and their patient population sizes. Journal of Cancer Policy, 2017, 14, 1-4.	1.4	5
80	The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. Journal of Market Access & Health Policy, 2017, 5, 1369817.	1.5	19
81	Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach. Influenza and Other Respiratory Viruses, 2017, 11, 543-555.	3.4	18
82	Quantifying the persisting orphan-drug shortage public health crisis in the United States. Journal of Market Access & Health Policy, 2017, 5, 1269473.	1.5	7
83	Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. Journal of Market Access & Health Policy, 2017, 5, 1307315.	1.5	39
84	Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment. Journal of Market Access & Health Policy, 2017, 5, 1344088.	1.5	17
85	Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines. Journal of Market Access & Health Policy, 2017, 5, 1355202.	1.5	2
86	Healthcare resource use in schizophrenia, EuroSC findings. Journal of Market Access & Health Policy, 2017, 5, 1372027.	1.5	8
87	A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. Journal of Market Access & Health Policy, 2017, 5, 1372026.	1.5	2
88	Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. Journal of Market Access & Health Policy, 2017, 5, 1298190.	1.5	13
89	Determinants of orphan drugs prices in France: a regression analysis. Orphanet Journal of Rare Diseases, 2017, 12, 75.	2.7	12
90	The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements. Applied Health Economics and Health Policy, 2017, 15, 5-11.	2.1	22

#	ARTICLE	IF	CITATIONS
91	Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. Journal of Market Access & Health Policy, 2016, 4, 32232.	1.5	3
92	Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. Journal of Market Access & Health Policy, 2016, 4, 33039.	1.5	16
93	Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients. Patient Preference and Adherence, 2016, 10, 27.	1.8	25
94	Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. Journal of Market Access & Health Policy, 2016, 4, 30725.	1.5	4
95	Advanced therapy medicinal products: current and future perspectives. Journal of Market Access & Health Policy, 2016, 4, 31036.	1.5	97
96	Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform. Journal of Market Access & Health Policy, 2016, 4, 30458.	1.5	9
97	About the advantages and disadvantages of discrete-event simulation for health economic analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 651-652.	1.4	0
98	Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. Psychiatry Research, 2016, 239, 301-307.	3.3	46
99	Overview of external reference pricing systems in Europe. Journal of Market Access & Health Policy, 2015, 3, 27675.	1.5	60
100	Current process and future path for health economic assessment of pharmaceuticals in France. Journal of Market Access & Health Policy, 2015, 3, 27902.	1.5	13
101	A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. Journal of Market Access & Health Policy, 2015, 3, 24966.	1.5	20
102	Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions. Journal of Market Access & Health Policy, 2015, 3, 25682.	1.5	6
103	Clinical management and associated costs for moderate and severe Alzheimer's disease in urban China: a Delphi panel study. Translational Neurodegeneration, 2015, 4, 15.	8.0	18
104	National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning. Journal of Market Access & Health Policy, 2015, 3, 29276.	1.5	5
105	Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophrenia. Psychiatry Research, 2015, 230, 860-866.	3.3	29
106	Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 565-578.	1.4	6
107	Sipuleucel-T (Provenge®) "Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. BioDrugs, 2015, 29, 301-307.	4.6	36
108	Recommendations for strengthening NITAG policies in developed countries. Vaccine, 2015, 33, 1-2.	3.8	8

#	ARTICLE	IF	CITATIONS
109	Comparison of NITAG policies and working processes in selected developed countries. <i>Vaccine</i> , 2015, 33, 3-11.	3.8	38
110	Fixing the Price of the Orphan Drug Siklos®: The Council of State Takes over the Decision. <i>European Journal of Health Law</i> , 2014, 21, 505-515.	0.2	5
111	Drug repurposing in pharmaceutical industry and its impact on market access: market access implications. <i>Journal of Market Access &amp; Health Policy</i> , 2014, 2, 22814.	1.5	10
112	Patient Reported Outcomes Instruments in Schizophrenia: A Review of Psychometric Properties. <i>Open Journal of Medical Psychology</i> , 2014, 03, 141-156.	0.5	8
113	New drug regulations in France: what are the impacts on market access? Part 1 " Overview of new drug regulations in France. <i>Journal of Market Access &amp; Health Policy</i> , 2013, 1, 20891.	1.5	19
114	A prospective study of health care resource utilisation and selected costs of schizophrenia in France. <i>BMC Health Services Research</i> , 2012, 12, 269-76.	2.2	21
115	Access to orphan drugs in Europe: current and future issues. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 23-29.	1.4	49
116	Design of Patient Access Schemes in the UK. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 209-215.	2.1	18
117	Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. <i>BMC Psychiatry</i> , 2011, 11, 24.	2.6	18
118	Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. <i>BMC Health Services Research</i> , 2011, 11, 259.	2.2	42
119	Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 22-28.	4.5	54
120	Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom " Findings from the European Schizophrenia Cohort (EuroSC). <i>European Psychiatry</i> , 2009, 24, 216-224.	0.2	27
121	Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC). <i>Psychological Medicine</i> , 2008, 38, 591-597.	4.5	37
122	Correlates of Subjective Quality of Life in People With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 87-94.	1.0	83
123	Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. <i>British Journal of Psychiatry</i> , 2007, 191, 30-37.	2.8	294
124	Burden on caregivers of people with schizophrenia: Comparison between Germany and Britain. <i>British Journal of Psychiatry</i> , 2007, 190, 333-338.	2.8	108
125	A prospective study of Quality of life in schizophrenia in three European countries. <i>Schizophrenia Research</i> , 2007, 93, 194-202.	2.0	61
126	Residential area and social contacts in schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007, 42, 617-622.	3.1	18



#	ARTICLE	IF	CITATIONS
127	The European Schizophrenia Cohort. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 707-717.	3.1	58